News & Press: Patient Safety

3/21 - Lidocaine Hydrochloride and 5% Dextrose Injection Safety Labeling Changes Approved By FDA Cen

Wednesday, March 20, 2013  
Share |

3/21 - Lidocaine Hydrochloride and 5% Dextrose Injection Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research February 2013

 

WARNINGS

• Anaphylactic reactions may occur following administration of lidocaine hydrochloride. In the case of severe reaction, discontinue the use of the drug.

 

ADVERSE REACTIONS

• Hematologic Effects: methemoglobinemia

• Allergic reactions, including anaphylactic reactions

Source: U.S. Food and Drug Administration (FDA) (Accessed: 3/19/2013)


Contact Us

120 E. Ogden Ave. Ste. 202
Hinsdale, Illinois 60521
P: 630.203.2252
Toll Free: 888.255.0005

© Copyright 2016 Spine Intervention Society Privacy Policy  ::  Legal